BofA Securities Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating
BofA Securities analyst Tazeen Ahmad maintains $Alnylam Pharmaceuticals(ALNY.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 53.0% and a total average return of 4.
TD Cowen Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $282
TD Cowen analyst Ritu Baral maintains $Alnylam Pharmaceuticals(ALNY.US)$ with a buy rating, and maintains the target price at $282.According to TipRanks data, the analyst has a success rate of 47.6%
TD Cowen Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Is Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Trading At A 49% Discount?
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years